The trial will include up to 78 patients with KRAS G12D-mutant pancreatic, colorectal, and non-small cell lung cancer.

The deal will bolster BMS's cell therapy efforts by adding Orbital's lead program in autoimmune diseases and RNA platform to its portfolio.

The company expanded the scope of the new Virginia plant to include a "state-of-the-art" antibody-drug conjugate manufacturing facility.

The grants were awarded under the EMBODY program, which is supporting development of in vivo cell therapy delivery platforms.

The company will provide CRO and testing services for the ADAPT program to guide the project's clinical trials.

The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...

The company is moving ahead with development plans after seeing positive data from a Phase I/II trial testing the diagnostic in neuroendocrine tumors.

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and ...

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

Rare Therapeutics will specifically advance gene therapies for extremely rare diseases with a goal of making them accessible globally.

Previously, the agency recommended doctors only discuss the risk of adverse events from chemotherapy for those with DPD deficiency.